<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="HSV-1 encephalitis compared with each drug given alone. Delay of" exact="treatment" post="with HBPG for up to two days was still"/>
 <result pre="a potent and safe combination therapy for the prevention and/or" exact="treatment" post="of HSV infection of the central nervous system can"/>
 <result pre="safe combination therapy for the prevention and/or treatment of HSV" exact="infection" post="of the central nervous system can improve the outcome"/>
 <result pre="the central nervous system can improve the outcome of this" exact="infection" post="in humans. antivirals herpetic encephalitis Introduction The major mucocutaneous"/>
 <result pre="lesion development, usually starting within six days of birth. If" exact="infection" post="results in disseminated disease, central nervous system (CNS) disease"/>
 <result pre="a superior antiviral drug which enters the CNS and inhibits" exact="infection" post="and related neurological sequellae. Recently we reported that an"/>
 <result pre="were maintained in an AAALAC accredited animal care facility. Ocular" exact="infection" post="Mice were anesthetized by intraperitoneal (IP) injection of ketamine"/>
 <result pre="were returned to their cages to recover from anesthesia. Intranasal" exact="infection" post="Mice were anesthetized as above and infected with 2"/>
 <result pre="were returned to their cages to recover from anesthesia. Drug" exact="treatment" post="Immediately following the infection and recovery from anesthesia, groups"/>
 <result pre="cages to recover from anesthesia. Drug treatment Immediately following the" exact="infection" post="and recovery from anesthesia, groups of 10 animals were"/>
 <result pre="that protected half of the animals. Statistical analysis Results of" exact="treatment" post="groups were compared to controls for significance by the"/>
 <result pre="test. Mean day of death (MDD) was calculated for each" exact="treatment" post="group and compared to controls for significance by the"/>
 <result pre="Antiviral activity is expressed as EC50. Results Various routes of" exact="infection" post="have been used to establish HSV encephalitis in mice,"/>
 <result pre="intranasal,9 intracerebral and IP,10,11 and intracutaneous.12 We used primarily ocular" exact="infection" post="(see below) for comparison of drug–drug combination efficacy. Mean"/>
 <result pre="comparison of drug–drug combination efficacy. Mean days of death after" exact="infection" post="(MDD) in untreated animals were usually 9–10 with HSV-1"/>
 <result pre="HSV-2 infections. For comparison, in one experiment we used intranasal" exact="infection" post="in which the MDDs for HSV-1 and HSV-2 were"/>
 <result pre="respectively. Effect of single drugs on HSV encephalitis The standard" exact="treatment" post="regimen of twice daily IP injections of compounds in"/>
 <result pre="HBPG protected animals from HSV-1 and/or HSV-2 encephalitic death following" exact="infection" post="by the ocular route in a dose dependent manner."/>
 <result pre="regimens of HBPG and CDF (data not shown). Delay of" exact="treatment" post="To compare the ability of HBPG to prevent an"/>
 <result pre="treatment To compare the ability of HBPG to prevent an" exact="infection" post="and to treat an established infection, the efficacy of"/>
 <result pre="for five days) against HSV-2 encephalitis was measured after initiating" exact="treatment" post="one, two, and three days after infection. The results,"/>
 <result pre="HBPG efficacy occurred, but that substantial protection remained even when" exact="treatment" post="began two full days after infection. Effect of drug"/>
 <result pre="HBPG was effective in protecting mice from death caused by" exact="infection" post="with HSV-1 and HSV-2. The compound is intermediate in"/>
 <result pre="observed when antiviral activities are directed against independent targets. The" exact="treatment" post="of HSV infection in the CNS requires that the"/>
 <result pre="activities are directed against independent targets. The treatment of HSV" exact="infection" post="in the CNS requires that the drug reach this"/>
 <result pre="at an effective concentration and in a timely manner. HSV" exact="infection" post="of an epithelial surface, for example the nasal passages"/>
 <result pre="of 10 mice were protected from HSV-2 encephalitic death when" exact="treatment" post="was begun two days after infection (Figure 1). In"/>
 <result pre="HSV-2 encephalitic death when treatment was begun two days after" exact="infection" post="(Figure 1). In contrast, little efficacy of ACV was"/>
 <result pre="the phosphonate compound CDF prevented lethality of herpes encephalitis when" exact="treatment" post="was delayed until four days postinfection.12 The observation that"/>
 <result pre="observation that HBPG exerts a protective effect two days after" exact="infection" post="indicates that the drug penetrates the CNS in a"/>
 <result pre="in the CNS? Based on the disastrous consequences of CNS" exact="infection" post="by HSV in encephalitis and neonates and our encouraging"/>
 <result pre="encouraging results indicating that mice can be protected against CNS" exact="infection" post="by HBPG and a combination of HBPG and ACV,"/>
 <result pre="this work. References References 1McGrathNAndersonNECroxsonMCPowellKFHerpes simplex encephalitis treated with acyclovir:" exact="diagnosis" post="and long term outcomeJ Neurol Neurosurg Psychiatry1997633213269328248 2WhitleyRJViral encephalitisNew"/>
 <result pre="kinasesJ Med Chem19953849577837239 8GebhardtBMVarnellEDHillJMKaufmanHEAnimal models of ocular herpes simplex virus" exact="infection" post="(rabbits, primates, mice)Handbook of Animal Models of InfectionChapter 110New"/>
 <result pre="of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)- cytosine in various models of herpes simplex virus" exact="infection" post="in miceAntimicrob Agents Chemother1991357017062069375 13ElionGBSingerSHitchingsGHAntagonists of nucleic acid derivatives"/>
 <result pre="200 300 cidofovir 3.2 2.4 HBPG 150 103 Notes: aOcular" exact="infection" post="with HSV-1 or HSV-2. bTreatment begun immediately after infection"/>
 <result pre="aOcular infection with HSV-1 or HSV-2. bTreatment begun immediately after" exact="infection" post="and continued twice daily (every 12 hours) IP for"/>
 <result pre="(Table 1) assuming additivity; Found, actual survival rate from combination" exact="treatment" post="(Table 2). Abbreviations: ACV, acyclovir; HSV, herpes simplex virus;"/>
</results>
